IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
University of Washington
CanariaBio Inc.
AstraZeneca
University of Alabama at Birmingham
Jiangsu Cancer Institute & Hospital
AstraZeneca
OHSU Knight Cancer Institute
Hospices Civils de Lyon
Zhejiang Cancer Hospital
AbbVie
Tesaro, Inc.
AbbVie
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC
University of Washington
Merck Sharp & Dohme LLC
Tesaro, Inc.
The University of Hong Kong
The University of Hong Kong
Universitaire Ziekenhuizen KU Leuven
Qilu Hospital of Shandong University
Anhui Provincial Cancer Hospital
Mercy Medical Center
Astex Pharmaceuticals, Inc.
University College, London
Albert Einstein College of Medicine
Medical College of Wisconsin
Loyola University
Merck Sharp & Dohme LLC
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Canadian Cancer Trials Group
National Cancer Institute, Naples
University of Kansas Medical Center
IRCCS Azienda Ospedaliero-Universitaria di Bologna
M.D. Anderson Cancer Center
University of Virginia
Fudan University
Masonic Cancer Center, University of Minnesota
Sotio Biotech Inc.
Saitama Medical University International Medical Center
Massachusetts General Hospital
National Cancer Institute (NCI)
University of Washington
Sotio Biotech Inc.
Bayer
Daiichi Sankyo
Professor Fernando Figueira Integral Medicine Institute
ChineseAMS
Eli Lilly and Company
Zhongshan Hospital Xiamen University